BridgeBio Pharma EBITDA 2018-2026 | BBIO
BridgeBio Pharma annual and quarterly EBITDA history from 2018 to 2026. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- BridgeBio Pharma EBITDA for the quarter ending June 30, 2026 was $-0.104B, a 20.85% decline year-over-year.
- BridgeBio Pharma EBITDA for the twelve months ending June 30, 2026 was $-0.486B, a 24.1% decline year-over-year.
- BridgeBio Pharma 2025 annual EBITDA was $-0.512B, a 11.64% decline from 2024.
- BridgeBio Pharma 2024 annual EBITDA was $-0.579B, a 2.12% decline from 2023.
- BridgeBio Pharma 2023 annual EBITDA was $-0.592B, a 17.12% increase from 2022.
|
BridgeBio Pharma Annual EBITDA (Millions of US $) |
|
|---|---|
| 2025 | $-512 |
| 2024 | $-579 |
| 2023 | $-592 |
| 2022 | $-505 |
| 2021 | $-571 |
| 2020 | $-473 |
| 2019 | $-265 |
| 2018 | $-184 |
| 2017 | $-44 |
|
BridgeBio Pharma Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2026-06-30 | $-104 |
| 2026-03-31 | $-103 |
| 2025-12-31 | $-132 |
| 2025-09-30 | $-147 |
| 2025-06-30 | $-132 |
| 2025-03-31 | $-101 |
| 2024-12-31 | $-217 |
| 2024-09-30 | $-190 |
| 2024-06-30 | $-174 |
| 2024-03-31 | $2 |
| 2023-12-31 | $-167 |
| 2023-09-30 | $-156 |
| 2023-06-30 | $-144 |
| 2023-03-31 | $-125 |
| 2022-12-31 | $-128 |
| 2022-09-30 | $-127 |
| 2022-06-30 | $-79 |
| 2022-03-31 | $-172 |
| 2021-12-31 | $-164 |
| 2021-09-30 | $-149 |
| 2021-06-30 | $-91 |
| 2021-03-31 | $-167 |
| 2020-12-31 | $-127 |
| 2020-09-30 | $-121 |
| 2020-06-30 | $-123 |
| 2020-03-31 | $-102 |
| 2019-12-31 | $-79 |
| 2019-09-30 | $-55 |
| 2019-06-30 | $-69 |
| 2019-03-31 | $-64 |
| 2018-09-30 | $-41 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $13.352B | $0.502B |
| BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |